Comparing two malaria treatments for P. vivax in people 2 and older
Treatments studied
Part of Infections clinical trials.
This study compares two medicines (tafenoquine and primaquine) taken with chloroquine to treat P. vivax malaria. It aims to see which is safer and works better in Indian participants aged 2 to 64.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and 64 years old, weighing more than 10 kg
- You have P. vivax malaria confirmed by a blood test with a certain amount of parasites
- Your hemoglobin level is above 8 g/dL (a measure of red blood cells)
- You have a fever now or had one in the past 48 hours
- Your G6PD enzyme level is normal (tested with a special device)
- If you are a woman of childbearing age, you must use effective birth control and have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This trial tests a two-drug combination to safely and quickly clear all stages of P. vivax malaria from your body. You must have confirmed vivax malaria, be within a certain weight range, and agree to hospital stay and follow-up visits over 6 months.
This trial tests the safety and immune response of an experimental vaccine called Vivaxin, designed to protect against malaria caused by the Plasmodium vivax parasite. Healthy adults aged 18–59 who have never had malaria may be able to join.
This trial tests whether a shorter course of primaquine can effectively prevent relapses of vivax malaria. It aims to make treatment easier and safer for patients.
This trial tests a revised dose of a medicine called tafenoquine to more effectively cure vivax malaria (a type of malaria that can come back). It is for people with normal G6PD enzyme levels and a current fever from vivax malaria.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
Hear when a new Malaria Vivax trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.